Organization
Kanglin Biotechnology (Hangzhou)
1 clinical trial
Clinical trial
A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2025-05-01